Biib stock price sensitivity to clinical data

BIIB stock price sensitivity to clinical data disclosure remains high. Traders are advised to monitor scheduled trial readouts as potential catalysts that could either accelerate upward moves or trigger risk-off selling. Biogen Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds . As per our database, 55 hedge fund portfolios held BIIB at the end of the second quarter which was 52 in the previous quarter. While we acknowledge the potential of BIIB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock . BIIB stock opened at $155.25 on Friday. Biogen Inc. has a 12 month low of $110.04 and a 12 month high of $194.13. The firm has a market cap of $22.76 billion, a PE ratio of 14.84, a P/E/G ratio of 1.22 and a beta of 0.13. The firm has a 50 day simple moving average of $137.45 and a 200 day simple moving average of $130.78. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.50 and a quick ratio of 1.79. With BIIB stock price hovering around $228–229, options market data shows increased call buying at the $240 strike expiring next month. This positioning reflects market participants betting on continued upward momentum following positive revenue guidance revisions.